After endometrial ablation, amenorrhea at 3 years was 21% with goserelin pretreatment versus 14% with sham pretreatment (estimated odds ratio 1.8, 95% CI 0.98-3.25; P=.0571).
In plain wordsAfter endometrial ablation, amenorrhea at 3 years was 21% with goserelin pretreatment versus 14% with sham; the odds ratio interval was 0.98 to 3.25.
- Peptide
- Goserelin
- Outcome
- IncreaseAmenorrhea at 3 years
- Study
n = 358
- Comparator
- sham depot before endometrial ablation
- Outcome group
- Sex hormones and fertility · Reproductive and sexual health
- Studied dose
- 3.6 mg depot every 28 days · 8 weeksAs given in this study (human).
Measurements
- Amenorrhea
- 21%
- goserelin
- Amenorrhea
- 14%
- control
- Odds ratio
- 1.8
- estimated
- 95% CI
- 0.98 to 3.25
- odds ratio
Source sentences
At 3 years, amenorrhea rates were 21% in the goserelin acetate group and 14% in the control group (estimated odds ratio, 1.8; 95% CI, 0.98-3.25; P=.0571).
3 context sentences(design, population, supporting numbers)
Prospective, randomized, double-blind, parallel-group study.
Three-hundred and fifty-eight premenopausal women aged over 30 years with DUB.
Goserelin acetate (3.6 mg depot) every 28 days for 8 weeks, or sham depot every 28 days for 8 weeks, with endometrial ablation 6 weeks +/- 3 days after the first depot injection (i.e., when the endometrium is at its thinnest).